Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Japanese Patients with CML or Ph+ ALL
NCT01667133Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Aug 2012
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib in chronic myeloid leukemia (CML) and Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoints: Dose-limiting Toxicities, Major Cytogenetic Response up to 60 months and 1 more. Started Aug 2012; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT01667133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667133.